Search
Close this search box.

Neurocrine’s Gorman to retire as CEO

ARTICLE | Management Tracks

Plus: Eisner becomes CMO of Vir and updates from Entact, Gates Medical Research Institute, Compass, Armonica and Omega

By Richard Guy, Biopharma Analyst, and Gunjan Ohri, Data Content Analyst

May 30, 2024 12:12 AM UTC

Kevin Gorman will retire as CEO of  Neurocrine Biosciences Inc. (NASDAQ:NBIX) in October while joining the neuro company’s board. Chief Business Development and Strategy Officer Kyle Gano will succeed him in the top spot. Neurocrine, which Gorman founded in 1992, markets Ingrezza valbenazine to treat tardive dyskinesia and chorea associated with Huntington disease.

Vir Biotechnology Inc. (NASDAQ:VIR) hired Mark Eisner as EVP and CMO, effective June 3. Eisner was CMO at Sonoma Pharmaceuticals Inc. (NASDAQ:SNOA). Former CMO Phil Pang left the company in March. …